G
REGN icon

GenTrust’s Regeneron Pharmaceuticals REGN Stock Holding History

GenTrust’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-859
Closed -$664K – 283
2026
Q1 		$664K Buy
859
+290
+51% +$222K 0.03% 136
2025
Q4 		$439K Buy
+569
New +$386K 0.02% 178
2022
Q3 		– Sell
-500
Closed -$296K – 140
2022
Q2 		$296K Buy
500
+200
+67% +$130K 0.02% 115
2022
Q1 		$210K Sell
300
-200
-40% -$127K 0.02% 137
2021
Q4 		$307K Buy
500
+96
+24% +$59K 0.02% 120
2021
Q3 		$244K Buy
404
+4
+1% +$2.48K 0.02% 131
2021
Q2 		$223K Buy
+400
New +$203K 0.02% 132
2020
Q4 		– Sell
-400
Closed -$224K – 153
2020
Q3 		$224K Sell
400
-10
-2% -$6.06K 0.02% 97
2020
Q2 		$256K Buy
+410
New +$233K 0.03% 86

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GenTrust's REGN Position: Q2 2026 in Review

GenTrust sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 859 shares — an estimated $664K sold.

GenTrust first reported a position in REGN in Q2 2020 and held it in 9 quarters. The position peaked at $664K in Q1 2026. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • GenTrust reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • GenTrust sold 859 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $664K.
  • GenTrust first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 9 quarters.
  • GenTrust's Regeneron Pharmaceuticals position peaked at $664K in Q1 2026.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on GenTrust's 13F filing for Q2 2026, filed 6 Aug 2026.